The Pursuit of Targeted Agents Broadens the HR+  Breast Cancer Treatment Paradigm Read More » June 28, 2024
Tucatinib-Based Regimen Improves Target Deficits, QOL in HER2+ Breast Cancer With Leptomeningeal Metastasis Read More » June 28, 2024
DESTINY-Breast Trial Portfolio Spotlights Efficacy of T-DXd in Metastatic Breast Cancer Read More » June 28, 2024
Trastuzumab Deruxtecan Effective For HR-Positive, HER2-Low Breast Cancer Treatment After Endocrine Therapy Read More » June 14, 2024
Inavolisib Plus Palbociclib/Fulvestrant Bolsters PFS in HR+/HER2–, PIK3CA-Mutant Breast Cancer Read More » June 14, 2024
Trastuzumab Deruxtecan Effective For HR-Positive, HER2-Low Breast Cancer Treatment After Endocrine Therapy Read More » June 14, 2024
Prospective Data Reveal Most Young Survivors of Breast Cancer Could Successfully Give Birth Read More » May 23, 2024
Inavolisib Receives FDA Breakthrough Therapy Designation for PIK3CA-Mutated, HR+/HER2– Breast Cancer Read More » May 21, 2024
